Alexandra Michelle Moreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Michelle Moreira has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Dawood Sayed
Department of Anesthesiology, The University of Kansas School of Medicine, Kansas City, MO 66160, USA
3 shared publications - Michael Schatman
Department of Anesthesiology, Perioperative Care, and Pain Medicine NYU Grossman School of Medicine New York NY USA
3 shared publications - Timothy Ray Deer
Spine and Nerve Center of the Virginias, West Virginia University, Thomas Health Campus, Charleston, WV 25309, USA
3 shared publications - Anuj Shah
Department of Physical Medicine and Rehabilitation, Detroit Medical Center, Detroit, MI, USA
2 shared publications - Christopher Massey
Pain Specialists of America, Austin, TX, USA
2 shared publications - Hemant Kalia
C.R.I.S.P Center for Research & Innovation in Spine & Pain, Rochester, NY, USA
2 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 6749-6768
Factors in Surgical Placement and System Design to Reduce Pocket Awareness and Optimize the User Experience of Spinal Cord Stimulators – A Comprehensive Review
Advancements in spinal cord stimulation (SCS) have enhanced patient outcomes, improved durability, and broadened the range of treatable pain conditions. Technological improvements in battery design have led to smaller implant size, while evolving societal guidelines have played a critical role in optimizing implant safety and quality. This review summarizes recent technological developments in SCS, the impact of such developments on patient satisfaction, and provides an overview of the major systems currently available. We also introduce and explore the emerging concept, “pocket awareness” – referring to a patient’s conscious perception of their implant. Several modifiable factors involving physicians, patients, and manufacturers can influence this awareness, and by extension, patient satisfaction. While pain relief is certainly the primary objective, fostering a comfortable and positive relationship between the patient and their device is essential and merits further clinical attention.
- 1 December 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 6749-6768
Open AccessFactors in Surgical Placement and System Design to Reduce Pocket Awareness and Optimize the User Experience of Spinal Cord Stimulators – A Comprehensive Review
Advancements in spinal cord stimulation (SCS) have enhanced patient outcomes, improved durability, and broadened the range of treatable pain conditions. Technological improvements in battery design have led to smaller implant size, while evolving societal guidelines have played a critical role in optimizing implant safety and quality. This review summarizes recent technological developments in SCS, the impact of such developments on patient satisfaction, and provides an overview of the major systems currently available. We also introduce and explore the emerging concept, “pocket awareness” – referring to a patient’s conscious perception of their implant. Several modifiable factors involving physicians, patients, and manufacturers can influence this awareness, and by extension, patient satisfaction. While pain relief is certainly the primary objective, fostering a comfortable and positive relationship between the patient and their device is essential and merits further clinical attention.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 4211-4235
Guidelines From the American Society of Pain and Neuroscience for Using Artificial Intelligence in Interventional Spine and Nerve Treatment
Introduction: Artificial intelligence (AI) is rapidly evolving and becoming more ubiquitous. Significant advancements have been made in the last few years, driving rapidly increasing adoption. The scale of publications on AI makes it difficult to keep abreast of relevant findings. Objective: The ASPN Artificial Intelligence Guidelines are designed to help clinicians understand AI and implement it into their practice. This Neuron Project is designed to evolve with the changing landscape of AI. Methods: An expert panel was chosen to discuss and write the best practice guidelines on AI. The primary authors conducted a literature search on PubMed, cross-referencing key terms in pain management and AI. After a thorough review of the current literature, the information collected was divided into broad categories of potential benefits, potential harms, and ways to ensure the benefits outweigh the potential harms of AI. These guidelines include only the most essential aspects of AI that clinicians need to know and understand before implementing AI into their practice. Results: Over 12,000 articles were found using the above search results. Many articles were reviews and clinical guidelines. The framework created from these guidelines allowed authors to fill in knowledge gaps and discuss the most critical elements pain clinicians should comprehend about AI. Conclusion: All authors achieved consensus on guidelines for implementing and using AI in pain management following a process of critical review and edits by the entire group of authors. All authors approved final guidelines. Discussion: The field of artificial intelligence is rapidly growing. As it expands into healthcare, it is necessary to prevent breaches of sensitive data and potential harm to patients. Guidelines that constantly evolve and grow with expanding indications for AI are essential to maximize benefit and prevent harm. This paper is part of ASPN’s Neuron Project and is designed to update continuously as this field evolves.
- 1 August 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 4211-4235
Open AccessGuidelines From the American Society of Pain and Neuroscience for Using Artificial Intelligence in Interventional Spine and Nerve Treatment
Introduction: Artificial intelligence (AI) is rapidly evolving and becoming more ubiquitous. Significant advancements have been made in the last few years, driving rapidly increasing adoption. The scale of publications on AI makes it difficult to keep abreast of relevant findings. Objective: The ASPN Artificial Intelligence Guidelines are designed to help clinicians understand AI and implement it into their practice. This Neuron Project is designed to evolve with the changing landscape of AI. Methods: An expert panel was chosen to discuss and write the best practice guidelines on AI. The primary authors conducted a literature search on PubMed, cross-referencing key terms in pain management and AI. After a thorough review of the current literature, the information collected was divided into broad categories of potential benefits, potential harms, and ways to ensure the benefits outweigh the potential harms of AI. These guidelines include only the most essential aspects of AI that clinicians need to know and understand before implementing AI into their practice. Results: Over 12,000 articles were found using the above search results. Many articles were reviews and clinical guidelines. The framework created from these guidelines allowed authors to fill in knowledge gaps and discuss the most critical elements pain clinicians should comprehend about AI. Conclusion: All authors achieved consensus on guidelines for implementing and using AI in pain management following a process of critical review and edits by the entire group of authors. All authors approved final guidelines. Discussion: The field of artificial intelligence is rapidly growing. As it expands into healthcare, it is necessary to prevent breaches of sensitive data and potential harm to patients. Guidelines that constantly evolve and grow with expanding indications for AI are essential to maximize benefit and prevent harm. This paper is part of ASPN’s Neuron Project and is designed to update continuously as this field evolves.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 3117-3139
Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project
Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach. Confusion exists on the use of a trial therapy, a permanent implant, and a 60-day duration treatment. The American Society of Pain and Neuroscience (ASPN) seeks to clarify the literature associated with this neuromodulation approach. A diverse group of experts was nominated to provide opinions and guidance based on evidence-graded assessment and clinical knowledge. This guidance is the first to specifically assess the clinical use of 60-day PNS and best medical practice.
- 1 June 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 3117-3139
Open AccessConsensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project
Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach. Confusion exists on the use of a trial therapy, a permanent implant, and a 60-day duration treatment. The American Society of Pain and Neuroscience (ASPN) seeks to clarify the literature associated with this neuromodulation approach. A diverse group of experts was nominated to provide opinions and guidance based on evidence-graded assessment and clinical knowledge. This guidance is the first to specifically assess the clinical use of 60-day PNS and best medical practice.
- Open Access
- 1 September 2024
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 2951-3001
Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group
Purpose: Injectable biologics have not only been described and developed to treat dermal wounds, cardiovascular disease, and cancer, but have also been reported to treat chronic pain conditions. Despite emerging evidence supporting regenerative medicine therapy for pain, many aspects remain controversial. Methods: The American Society of Pain and Neuroscience (ASPN) identified the educational need for an evidence-based guideline on regenerative medicine therapy for chronic pain. The executive board nominated experts spanning multiple specialties including anesthesiology, physical medicine and rehabilitation, and sports medicine based on expertise, publications, research, and clinical practice. A steering committee selected preliminary questions, which were reviewed and refined. Evidence was appraised using the United States Preventive Services Task Force (USPSTF) criteria for evidence level and degree of recommendation. Using a modified Delphi approach, consensus points were distributed to all collaborators and each collaborator voted on each point. If collaborators provided a decision of “disagree” or “abstain”, they were invited to provide a rationale in a non-blinded fashion to the committee chair, who incorporated the respective comments and distributed revised versions to the committee until consensus was achieved. Results: Sixteen questions were selected for guideline development. Questions that were addressed included type of injectable biologics and mechanism, evidence in treating chronic pain indications (eg, tendinopathy, muscular pathology, osteoarthritis, intervertebral disc disease, neuropathic pain), role in surgical augmentation, dosing, comparative efficacy between injectable biologics, peri-procedural practices to optimize therapeutic response and quality of injectate, federal regulations, and complications with mitigating strategies. Conclusion: In well-selected individuals with certain chronic pain indications, use of injectable biologics may provide superior analgesia, functionality, and/or quality of life compared to conventional medical management or placebo. Future high-quality randomized clinical trials are warranted with implementation of minimum reporting standards, standardization of preparation protocols, investigation of dose–response associations, and comparative analysis between different injectable biologics.
- 1 September 2024
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 2951-3001
Open AccessEvidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain: A Consensus Report from a Multispecialty Working Group
Purpose: Injectable biologics have not only been described and developed to treat dermal wounds, cardiovascular disease, and cancer, but have also been reported to treat chronic pain conditions. Despite emerging evidence supporting regenerative medicine therapy for pain, many aspects remain controversial. Methods: The American Society of Pain and Neuroscience (ASPN) identified the educational need for an evidence-based guideline on regenerative medicine therapy for chronic pain. The executive board nominated experts spanning multiple specialties including anesthesiology, physical medicine and rehabilitation, and sports medicine based on expertise, publications, research, and clinical practice. A steering committee selected preliminary questions, which were reviewed and refined. Evidence was appraised using the United States Preventive Services Task Force (USPSTF) criteria for evidence level and degree of recommendation. Using a modified Delphi approach, consensus points were distributed to all collaborators and each collaborator voted on each point. If collaborators provided a decision of “disagree” or “abstain”, they were invited to provide a rationale in a non-blinded fashion to the committee chair, who incorporated the respective comments and distributed revised versions to the committee until consensus was achieved. Results: Sixteen questions were selected for guideline development. Questions that were addressed included type of injectable biologics and mechanism, evidence in treating chronic pain indications (eg, tendinopathy, muscular pathology, osteoarthritis, intervertebral disc disease, neuropathic pain), role in surgical augmentation, dosing, comparative efficacy between injectable biologics, peri-procedural practices to optimize therapeutic response and quality of injectate, federal regulations, and complications with mitigating strategies. Conclusion: In well-selected individuals with certain chronic pain indications, use of injectable biologics may provide superior analgesia, functionality, and/or quality of life compared to conventional medical management or placebo. Future high-quality randomized clinical trials are warranted with implementation of minimum reporting standards, standardization of preparation protocols, investigation of dose–response associations, and comparative analysis between different injectable biologics.